



AT-GC BioPharm Files Provisional Patent Applications on Signature Manufacturing for Biopharmaceuticals

AT-GC BioPharm (Clarksburg, MD) announced that it has filed a provisional patent application covering the method and system for a raw material management system for biomanufacturing. The raw material monitor along with product monitor and 'electronic eye' technology constitutes the heart of its signature manufacturing platform for biopharmaceutical manufacturing.

Source: AT-GC BioPharm.

AT-GC BioPharm Files Provisional Patent Applications on Signature Manufacturing for Biopharmaceuticals

Washington DC (PRWeb) August 26, 2003 — AT-GC BioPharm (Clarksburg, MD) announced that it has filed a provisional patent application covering the method and system for a raw material management system for biomanufacturing. The raw material monitor along with product monitor and 'electronic eye' technology constitutes the heart of its signature manufacturing platform for biopharmaceutical manufacturing.

AT-GC BioPharm is developing a standardized manufacturing platform that uses its proprietary "Electronic Eye" technology that assures product quality in all parts of the drug development chain from vector through patient. The signature manufacturing platform allows biopharmaceutical companies' ability to move product that is consistent in quality to 'first in patient' as soon as possible and then focus on life cycle management which will give them the competitive edge.

AT-GC BioPharm's key to success is to integrate the process development with manufacturing with consistent quality control and assurance. Another important aspect of the company's technology is multiple sourcing for all products. The company is also cautious about the impact of changes in process upon the quality of the product. AT-GC BioPharm plans to start GLP and GMP manufacture of nucleic acid and protein based products by first quarter of 2004. In addition, AT-GC BioPharm has programs focused on the development of efficient drug delivery systems for gene and protein based therapeutics.

Included in this release are "forward-looking" statements. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although AT-GC BioPharm believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. AT-GC BioPharm's actual results could differ materially from those anticipated in the forward-looking statements as a result of various factors.

Contact:

For AT-GC BioPharm
Roshni Mehta, 301-793-0644
www.at-gc.com

Contact Information

Jenny Smith
AT-GC BioPharm
<http://www.at-gc.com>
301-540-5474